Mr. Baldor joined Vivani Medical as Chief Financial Officer in 2025, bringing over 20 years of experience in biotechnology finance, strategy, and business development. Prior to Vivani, he served as CFO and Head of Business Development at Diakonos Oncology, where he led fundraising, investor relations, and early partnering activities. From 2019 to 2023, Mr. Baldor was Vice President of Corporate Strategy and Development at 4D Molecular Therapeutics (NASDAQ: FDMT), where he played a central role in the company’s Series C financing, IPO, and multiple strategic transactions, including the partnership with Astellas Pharmaceuticals and the acquisition of Aevitas Therapeutics, among others. Earlier in his career, Mr. Baldor held roles in equity research at Jefferies, venture capital at BioInnovation Capital and RMI Partners, and business development at several early-stage biotech companies. He began his career in immunology and oncology research at the Harvard Skin Disease Research Center at Brigham and Women’s Hospital, and Dana-Farber. Mr. Baldor earned an M.B.A. and Masters in Data Science from the University of California, Berkeley, and a B.A. in Neuroscience from Vassar College.